Search Studies
Research studies are looking for volunteers just like you. Both healthy volunteers and participants with specific health conditions are needed to help answer important questions impacting the health of our friends and family. Join us to improve the health of others.
-
Single-Dose Investigational Drug Study for Depression and Anxiety
Official Title A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants with Major Depressive Disorder (MDD) and Moderate to Severe AnxietyPurpose
The aim of this study is to determine the effects of one administration of the psychedelic compound CYB003 on depression and anxiety symptoms as well as its effects on brain function.
Could this study be right for you?
1. Currently have depression with moderate to severe anxiety
2. Are currently taking an antidepressant and your symptoms have not improved enough
3. Have been on the same antidepressant dose for about 1 month
Age Range
21 - 65 years -
EEG Research Study
Official Title Neural Biomarkers of Sensory Symptoms in AutismPurpose
This research aims to understand how sensory issues, particularly related to hearing, impact children on the autism spectrum. Using a tool called EEG, we study how their brains respond to sounds. Previous research with adults on the spectrum showed that their brains react more slowly to sounds, affecting their ability to pay attention. This protocol investigates if a similar pattern exists in children with autism.
Could this study be right for you?
We are searching for healthy neurotypical boys aged 8-12.
Age Range
8 - 12 years -
A Study about how virtual Yoga sessions affect symptoms and quality of life in patients with diabetic gastroparesis
Official Title The Effect of Virtual Yoga Intervention on Symptom Severity and Quality of Life in Patients with Diabetic GastroparesisPurpose
The purpose of this research study is to understand how virtual Yoga sessions conducted 4 days a week for 12 weeks affect digestive symptoms and quality of life in those suffering from gastroparesis due to diabetes mellitus.
Could this study be right for you?
- Able to understand English
- Must have been diagnosed with gastroparesis
- Must have type 1 or type 2 diabetes mellitusAge Range
18 - 65 years -
Clinical Trial Involving Monthly Injections for Osteogenesis Imperfecta (OI)
Official Title A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI)Purpose
The reason for this study is to see if the investigational drug, called AGA2115, can help increase bone mineral density in people with osteogenesis imperfecta. AGA2115 or a placebo drug will be given at the clinic once a month subcutaneously. During this study, changes in bone biomarkers, number of bone fractures, and quality of life, will be measured to see if AGA2115 can help people with osteogenesis imperfecta. This study will also look at how the body absorbs, breaks down and gets rid of AGA2115 (called pharmacokinetics), if AGA2115 affects any markers of bone metabolism in the body, if the body’s natural defense system (the immune system) tries to make antibodies to AGA2115 (called immunogenicity) and how well people feel while taking AGA2115, including any side effects they may have.
You will be asked to complete the following: perform monthly injections, take Vitamin D and Calcium supplements, perform ECGs and DEXA scans, provide blood samples, perform grip strength tests, do hearing tests (called Audiometry and Tympanometry), complete questionnaires, undergo a one-time bone biopsy, and see the study doctor.
If you do not have genetic confirmation of osteogenesis imperfecta, we may be able to test for it through the study.
The study will last 27 months.
Could this study be right for you?
The most important eligibility criteria include the following. This is not an expansive list.
- Genetic confirmation of Osteogenesis Imperfecta Type I, III, or IV diagnosis
- DXA scan assessing L1-L4 region
- BMD T-score <= -1.0 at lumber spine OR total hip OR femoral neck
- Cannot be taking IV or oral bisphosphonate with the past 6 months
Age Range
18 - 75 years -
Heart2Heart Research Study
Official Title Creating a Mobile Health Program for Teens with Congenital Heart Disease (“Heart2Heart Research Study”)Purpose
The study aims to understand what teens with congenital heart disease want and need in mobile health program that helps them learn about their heart health and overall wellness.
Could this study be right for you?
Enrollment is by invitation only. The study team will contact you if you are eligible to participate.
Age Range
12 - 18 years -
"Debio-4126" for patients with Acromegaly currently taking octreotide ("Sandostatin" or "Mycapssa") or lanreotide ("Somatuline") with Dr. Luma Ghalib, MD.
Official Title "A Phase 3 randomized 3-arm trial (double-blind Debio 4126, placebo control, and open-label Debio 4126), to assess the efficacy and safety of Debio 4126, a 12-week octreotide formulation, in patients with acromegaly previously treated with somatostatin analogs"Purpose
The purpose of this trial is to see if the study medication "Debio-4126" can safely maintain a low level of growth hormone ("GH") and insulin-like growth factor 1 ("IGF‑1") lab values for patients diagnosed with Acromegaly.
You will be asked to come to visits 1-2 times a month and receive an injection every 12 weeks at our clinic.
At clinic visits, you will be asked to answer questions about your medical history, speak to the study doctor, provide blood and urine samples, do ECGs and other imaging techniques, receive the study medication, and complete questionnaires. Not all of these will be done at every visit. Visits will take place at Outpatient Care East.
This study will use a computer to randomly assign you to the study medication ("Debio-4126") or a placebo, which has no therapeutic effect on the body, commonly referred to as a "sugar pill".
You have 5 chances out of 7 of receiving the study medication.If you are assigned the placebo, you will have a chance to receive the study medication later in the study.
If you are eligible, your participation in this trial will last between 10 to 29 months depending on whether the trial drug is safe and works for you.
If you have any questions about this study, please don't hesitate to reach out to Hangil at 614-814-0809 or email at hangil.kim@osumc.edu.
Could this study be right for you?
Most Important Eligibility Criteria
- Over the age of 18 years old
- Have an official Acromegaly diagnosis
- Currently taking Octreotide or Lanreotide (ex. "Sandostatin", "Mycapssa", "Somatuline", etc...) at any dose for 6 months and on the same dose for the past 3 months.
- Controlled IGF-1 lab values
- Must not have had radiation on pituitary gland in the past
- Must not currently be taking pasireotide (Signifor), pegvisomant (Somavert), or dopamine agonists (Cabergoline)
Age Range
18 - 75 years - Over the age of 18 years old
-
A Study of Psilocybin-Assisted Therapy for Adults with Posttraumatic Stress Disorder (PTSD)
Official Title A Randomized Mechanistic Study of Effect of Psilocybin Combined with Mindfulness-based Therapy vs Support on Posttraumatic Stress Disorder (PTSD)Purpose
This study will look at the effects of psilocybin-assisted therapy on brain function and mental health. If eligible, you will be asked to complete brain scans (fMRI, EEG), blood tests, and surveys about your mental health before and after you receive a dose of psilocybin. In addition, you will participate in virtual and in-person therapy sessions.
Could this study be right for you?
General Inclusion Criteria:
- Been diagnosed with Posttraumatic Stress Disorder (PTSD) and experiencing active symptoms
- Experiencing active depression symptoms
General Exclusion Criteria:
- Diagnosis of cardiovascular disease, hypertension, or arrhythmia
- Current or past diagnosis of schizophrenia spectrum or other psychotic disorders
- Clinically significant medical or neurological condition
- History of substance use disorder within the past 12 months
Age Range
21 - 65 years -
Comparing Tongue Strength and Endurance Before and After Eating a Meal
Official Title Impact of Meal Consumption on Lingual EndurancePurpose
The purpose of this study is to understand how eating a meal can affect muscle fatigue in the tongue in individuals with swallowing difficulties due to a neurological disorder or history of a stroke.
If you choose to participate, you will:
- Complete questionnaires about your swallowing and overall health.
- Participate in measurements of your tongue strength using a small, soft bulb placed in your mouth.
- Eat a standard meal of chicken, masked potatoes and green beans.
- Remeasure your tongue and grip strength after the meal
This study is completed in 1 session that lasts approximately 90 minutes.
Could this study be right for you?
- 18 years of age or older
- Report at least some signs/symptoms of difficulty swallowing (dysphagia)
- Have a diagnosed neurological disorder
- English speaking
- Able to eat a standardized meal of chicken, green beans and mashed potatoes
- Adequate dexterity to self-administer foods and drink via fork and cup
Age Range
18 - 100 years -
Food and Fitness with Medicine
Official Title Food and Fitness with MedicinePurpose
We are conducting a new study to explore whether a supportive program that combines healthy eating, enjoyable physical activity, and practical resources can improve health in postmenopausal women living with heart, kidney, or metabolic conditions who are using weight‑management medications. As more women use these medications, researchers want to understand how they can be paired with supportive lifestyle changes like nourishing food and enjoyable movement to improve overall health.
As more women turn to these medications, there is an important need to understand how they work best alongside real‑world lifestyle supports. This study aims to answer that question.
Depending on your group, you may also take part in activities such as personalized nutrition counseling, cooking demonstrations, groceries or vouchers, structured fitness, and optional online or at‑home resources. The goal of this research is to understand what truly helps people build and maintain healthy habits over time. By participating, you can contribute to research that will help guide future care and improve health programs for women like you.
Could this study be right for you?
Eligibility criteria:
- Post-menopausal
- Have at least one of the following conditions: hypertension, type 2 diabetes, high triglycerides, metabolic syndrome, moderate CKD
- Plan to start a GLP-1 medication or have started a GLP-1 medication within the last 6 weeks
Age Range
45 - 79 years -
Using Mobile Technology to Improve Body Composition Assessment and Track Physical Activity in Adults with Down Syndrome
Official Title Improving Body Composition Assessment and Physical Activity Monitoring in Adults with Down Syndrome using Mobile Technology
Purpose
The purpose of this study is to learn how well wearable technologies, such as smartwatches and activity trackers, can measure body composition and physical activity in adults with Down syndrome. Adults with Down syndrome are at a higher risk for obesity and related health conditions, and current methods used to measure body composition and activity can be difficult or uncomfortable. This study aims to identify simpler and more comfortable ways to collect this information.
If you choose to participate, you will be asked to attend one in-person study visit at a research laboratory. During this visit, you will complete a series of body measurements and light physical activity tasks. These include providing a small urine sample to check hydration, having your height, weight, and body composition measured using several methods (including a scan where you lie still for several minutes), and completing strength and walking tests. You will also wear multiple activity tracking devices on different parts of your body while completing short walking activities.
Your total time involved in this study will be one visit lasting approximately a few hours.
Could this study be right for you?
- Adult diagnosed with Down Syndrome
- Weight <350 lbs
- No condition that impacts body composition assessments (e.g., pacemaker)
- Not pregnant or planning to become pregnant
Age Range
18 - 60 years -
Evaluating the Efficacy of a Psychedelic Investigational Drug for Patients who are Struggling with Symptoms of Depression and Anxiety due to Cancer or Other Life-Changing Medical Illness
Official Title A Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Adjustment Disorder in Patients with Cancer and Other Medical IllnessesPurpose
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.
Could this study be right for you?
- Depression due to cancer, Parkinson’s, ALS, MS, or IPF
- Currently depressed
- Projected life expectancy of ≥6 months.
Age Range
18 - 80 years -
Evaluating the Safety and Efficacy of Icalcaprant in the Treatment of Subjects with Major Depressive Disorder (MDD)
Official Title A Phase 2, Multicenter, 6-Week, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Icalcaprant in Subjects with Major Depressive DisorderPurpose
Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and serious illness that can cause both emotional and physical symptoms such as feelings of sadness, irritability, not being able to focus on activities, tiredness, changes in eating habits, and aches and pains.
This study will assess the changes in disease activity and adverse events of oral Icalcaprant in adult participants with major depressive disorder who are currently experiencing a major depressive episode (MDE).
Could this study be right for you?
- Diagnosed with MDD
- Current major depressive episode
- Willing to discontinue antidepressant treatments
Age Range
18 - 65 years